ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tucidinostat

Also written as “Chidamide”, “Tucidinostat” and “HBI-8000”.

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Melanoma · Breast Neoplasms · Lymphoma, Non-Hodgkin, led by 4 companies.

Drug pageTucidinostat: every studyAll 185 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 17, 201519 company-led studies, 5 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chipscreen Biosciencesits history only92 open or runningphase 3since Jun 17, 2015Apr 12, 2013May 31, 2028phase 3 · NCT06497985
HUYABIO International, LLC.its history only71 open or runningphase 3since Dec 7, 2020Oct 5, 2015none ahead
Great Novel Therapeutics Biotech & Medicalsits history only21 open or runningphase 2since Feb 7, 2023Feb 7, 2023Jun 2027phase 2 · NCT05833724
Jiangsu HengRui Medicine11 open or runningphase 3since Nov 5, 2023Nov 5, 2023none ahead

Also a collaborator on its studies: Bristol-Myers Squibb and Iqvia Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jiangsu HengRui Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2016Named tucidinostatINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HBI-8000
  2. Nov 5, 2023First study: phase 3 study in RecurrenceFirst studyNCT06122389 · 130 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Jiangsu HengRui Medicine leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06122389Recurrence · China3RecruitingMay 2026130

How it is read

Names in the registry

  • “Chidamide”, 7 entries
  • “Tucidinostat”, 4 entries
  • “HBI-8000”, 4 entries
  • “HBI-8000 in combination with nivolumab”, 2 entries
  • “SHR2554 analog tablets; Chidamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.